Results
622
Gain exposure to companies in the healthcare sector with a strong future outlook and robust financials.
622 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
DOC | AU$0.07 | -3.4% | 17.5% | AU$26.0m | n/a | PB4.6x | E108.0% | n/a | ||
DOC | AU$0.071 | -2.7% | 18.3% | AU$26.0m | n/a | PB4.6x | E108.0% | n/a | ||
NXGL | US$2.59 | -5.5% | 22.2% | US$17.5m | US$6.00 | PS3.5x | E70.5% | n/a | ||
0I0L | €4.11 | 0% | n/a | €15.5m | €3.10 | PB0.4x | E133.9% | 0% | ||
IME | AU$0.48 | -4.0% | -20.0% | AU$21.9m | AU$1.15 | PB1.4x | E111.2% | n/a | ||
IME | AU$0.48 | 0% | -20.0% | AU$21.9m | AU$1.15 | PB1.4x | E111.2% | n/a | ||
NOSA | SEK 0.60 | -5.5% | -35.1% | SEK 126.1m | n/a | PS10x | E87.4% | n/a | ||
AOHA | UK£0.10 | -2.8% | -26.8% | UK£7.4m | n/a | PS3.4x | E98.2% | n/a | ||
RUA | UK£0.12 | -2.0% | -23.8% | UK£7.4m | n/a | PS3.4x | E98.2% | n/a | ||
HY11 | US$1.87 | 0% | -83.3% | US$8.4m | US$32.08 | PB0.5x | E64.5% | n/a | ||
OTRK | US$2.63 | -16.1% | -79.7% | US$8.4m | US$45.00 | PB0.5x | E64.5% | n/a | ||
KONT | SEK 2.38 | -8.5% | -6.3% | SEK 76.3m | SEK 5.80 | PE43.6x | E85.4% | n/a | ||
3KT | SEK 0.18 | 2.8% | 2.2% | SEK 76.3m | n/a | PE43.6x | E85.4% | n/a | ||
ADRDA | AU$0.031 | 14.8% | n/a | AU$10.3m | n/a | PS3.2x | E97.7% | n/a | ||
ADR | AU$0.014 | 16.7% | -76.7% | AU$9.1m | n/a | PS10.8x | E73.7% | n/a | ||
ADR | AU$0.012 | -7.7% | -80.0% | AU$9.1m | n/a | PS10.8x | E73.7% | n/a | ||
S1K | US$0.74 | 0% | n/a | US$5.2m | US$2.84 | PS3x | E72.4% | n/a | ||
POAI | US$0.79 | -3.7% | -75.4% | US$5.2m | US$3.00 | PS3x | E72.4% | n/a | ||
26H | US$5.40 | 0% | -55.7% | US$3.7m | US$139.37 | PS4.6x | E69.6% | n/a | ||
E1Z | US$0.22 | -21.1% | n/a | US$2.2m | US$4.48 | PS1.5x | E147.0% | n/a | ||
CTQ | AU$0.012 | 0% | -45.5% | AU$2.8m | n/a | PB1.4x | E126.2% | n/a | ||
CTQ | AU$0.012 | 0% | -45.5% | AU$2.8m | n/a | PB1.4x | E126.2% | n/a |